- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Volume 2012 (2012), Article ID 620834, 12 pages
Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST
1Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
2Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA
3Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA
4Brain Tumor Program, University of Minnesota, Minneapolis, MN 55455, USA
5Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
6Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA
7Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Research Foundation, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
8Division of Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Research Foundation, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
9UF Shands Cancer Center, Genetics Institute, University of Florida, Gainesville, FL 32610, USA
10Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
Received 6 August 2012; Accepted 2 November 2012
Academic Editor: R. Pollock
Copyright © 2012 Vincent W. Keng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. P. Boyd, B. R. Korf, and A. Theos, “Neurofibromatosis type 1,” Journal of the American Academy of Dermatology, vol. 61, no. 1, pp. 1–14, 2009.
- J. M. Friedman, “Epidemiology of neurofibromatosis type 1,” American Journal of Medical Genetics, vol. 89, no. 1, pp. 1–6, 1999.
- A. Rosenfeld, R. Listernick, J. Charrow, and S. Goldman, “Neurofibromatosis type 1 and high-grade tumors of the central nervous system,” Child's Nervous System, vol. 26, no. 5, pp. 663–667, 2010.
- E. Beert, H. Brems, B. Daniels, et al., “Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors,” Genes Chromosomes Cancer, vol. 50, no. 12, pp. 1021–1032, 2011.
- F. Perrone, L. Da Riva, M. Orsenigo et al., “PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor,” Neuro-Oncology, vol. 11, no. 6, pp. 725–736, 2009.
- I. Bottillo, T. Ahlquist, H. Brekke et al., “Germline and somatic NFI mutations in sporadic and NFI-associated malignant peripheral nerve sheath tumours,” Journal of Pathology, vol. 217, no. 5, pp. 693–701, 2009.
- M. C. Hollander, G. M. Blumenthal, and P. A. Dennis, “PTEN loss in the continuum of common cancers, rare syndromes and mouse models,” Nature Reviews Cancer, vol. 11, no. 4, pp. 289–301, 2011.
- C. Gregorian, J. Nakashima, S. M. Dry et al., “PTEN dosage is essential for neurofibroma development and malignant transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 46, pp. 19479–19484, 2009.
- V. W. Keng, E. P. Rahrmann, A. L. Watson, et al., “PTEN and NF1 inactivation in schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors,” Cancer Research, vol. 72, no. 13, pp. 3405–3413, 2012.
- M. Aoki, K. Nabeshima, K. Koga et al., “Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB,” Laboratory Investigation, vol. 87, no. 8, pp. 767–779, 2007.
- J. E. DeClue, S. Heffelfinger, G. Benvenuto et al., “Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models,” Journal of Clinical Investigation, vol. 105, no. 9, pp. 1233–1241, 2000.
- A. Perry, S. N. Kunz, C. E. Fuller et al., “Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 8, pp. 702–709, 2002.
- B. C. Ling, J. Wu, S. J. Miller et al., “Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis,” Cancer Cell, vol. 7, no. 1, pp. 65–75, 2005.
- O. Maertens, H. Brems, J. Vandesompele et al., “Comprehensive NF1 screening on cultured Schwann cells from neurofibromas,” Human Mutation, vol. 27, no. 10, pp. 1030–1040, 2006.
- E. Serra, E. Ars, A. Ravella et al., “Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations,” Human Genetics, vol. 108, no. 5, pp. 416–429, 2001.
- E. Serra, S. Puig, D. Otero et al., “Confirmation of a double-hit model for the NF1 gene in benign neurofibromas,” American Journal of Human Genetics, vol. 61, no. 3, pp. 512–519, 1997.
- A. Xiao, C. Yin, C. Yang, A. Di Cristofano, P. P. Pandolfi, and T. Van Dyke, “Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation,” Cancer Research, vol. 65, no. 12, pp. 5172–5180, 2005.
- M. Jaegle, M. Ghazvini, W. Mandemakers et al., “The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development,” Genes and Development, vol. 17, no. 11, pp. 1380–1391, 2003.
- D. H. Viskochil, “It takes two to tango: mast cell and Schwann cell interactions in neurofibromas,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1791–1793, 2003.
- A. O. Stemmer-Rachamimov, D. N. Louis, G. P. Nielsen et al., “Comparative pathology of nerve sheath tumors in mouse models and humans,” Cancer Research, vol. 64, no. 10, pp. 3718–3724, 2004.
- W. A. Weiss, M. Israel, C. Cobbs et al., “Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum,” Oncogene, vol. 21, no. 49, pp. 7453–7463, 2002.
- Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” Journal of the Royal Statistical Society B, vol. 57, no. 1, pp. 289–300, 1995.
- M. Dai, P. Wang, A. D. Boyd et al., “Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data,” Nucleic Acids Research, vol. 33, no. 20, pp. e175.1–e175.9, 2005.
- D. Muir, D. Neubauer, I. T. Lim, A. T. Yachnis, and M. R. Wallace, “Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells,” American Journal of Pathology, vol. 158, no. 2, pp. 501–513, 2001.
- K. Yusa, L. Zhou, M. A. Li, A. Bradley, and N. L. Craig, “A hyperactive piggyBac transposase for mammalian applications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1531–1536, 2011.
- A. F. Buckley, L. J. Burgart, V. Sahai, and S. Kakar, “Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma,” American Journal of Clinical Pathology, vol. 129, no. 2, pp. 245–251, 2008.
- T. Rajkumar and W. J. Gullick, “The type I growth factor receptors in human breast cancer,” Breast Cancer Research and Treatment, vol. 29, no. 1, pp. 3–9, 1994.
- L. F. Lopes and C. E. Bacchi, “EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases,” Modern Pathology, vol. 20, no. 9, pp. 990–994, 2007.
- A. Villanueva, D. Y. Chiang, P. Newell et al., “Pivotal role of mTOR signaling in hepatocellular carcinoma,” Gastroenterology, vol. 135, no. 6, pp. 1972.e11–1983.e11, 2008.
- D. Keizman, J. Issakov, I. Meller et al., “Expression and significance of EGFR in malignant peripheral nerve sheath tumor,” Journal of Neuro-Oncology, vol. 94, no. 3, pp. 383–388, 2009.
- Y. Yarden, “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities,” European Journal of Cancer, vol. 37, supplement 4, pp. S3–S8, 2001.
- T. Ettl, K. Baader, C. Stiegler, M. Muller, A. Agaimy, J. Zenk, et al., “Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer,” British Journal of Cancer, vol. 106, no. 4, pp. 719–726, 2012.